CytoMed Therapeutics Limited Ordinary Shares Total Liabilities
CytoMed Therapeutics Limited Ordinary Shares total liabilities. Based on the latest financial reports, CytoMed Therapeutics Limited Ordinary Shares (GDTC) has total liabilities worth $1.13 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CytoMed Therapeutics Limited Ordinary Sh liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Total liabilities of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025. This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Explore how much of CytoMed Therapeutics Limited Ordinary Sh's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CytoMed Therapeutics Limited Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of CytoMed Therapeutics Limited Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Titan Logix Corp.
V:TLA
|
Canada | CA$1.01 Million |
|
BSA Ltd
AU:BSA
|
Australia | AU$8.38 Million |
|
ERG S.A.
WAR:ERG
|
Poland | zł28.53 Million |
|
CoinSmart Financial Inc
NEO:SMRT
|
Canada | CA$61.00 Million |
|
Entero Therapeutics, Inc.
NASDAQ:ENTO
|
USA | $45.81 Million |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
India | Rs-691.15 Million |
|
DCI O.N.
F:DCIK
|
Germany | €259.86K |
|
Modular Medical Inc
NASDAQ:MODD
|
USA | $4.38 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down CytoMed Therapeutics Limited Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CytoMed Therapeutics Limited Ordinary Sh total assets.
Liquidity & Leverage Metrics
CytoMed Therapeutics Limited Ordinary Shares Total Liabilities Ratios Explained
CytoMed Therapeutics Limited Ordinary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CytoMed Therapeutics Limited Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
The table below shows the annual total liabilities of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.13 Million | +10.51% |
| 2024-12-31 | $1.02 Million | -9.23% |
| 2023-12-31 | $1.13 Million | -75.81% |
| 2022-12-31 | $4.66 Million | +33.25% |
| 2021-12-31 | $3.50 Million | +4.55% |
| 2020-12-31 | $3.35 Million | +232.14% |
| 2019-12-31 | $1.01 Million | -- |
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I… Read more